Citations

Clear

1446 citation(s) found for "Howard, F".

TERT gene harbors multiple variants associated with pancreatic cancer susceptibility
Campa, Daniele , Rizzato, Cosmeri , Pacetti, Paola, Vodička, Pavel , Cleary, Sean P. , Capurso, Gabriele , Bueno‐de‐Mesquita, H. Bas, Werner, Jens , Butterbach, Katja, Ivanauskas, Audrius , Giese, Nathalia A. , Petersen, Gloria M. , Fogar, Paola, Bassi, Claudio , Ryska, Miroslav , Theodoropoulos, George , Li, Donghui , Greenhalf, William , Pasquali, Claudio , Hackert, Thilo , Fuchs, Charles S. , Mohelníková-Duchoňová, Beatrice , Funel, Niccola , Dieffenbach, Aida Karina, Buring, Julie E. , Holcátová, Ivana , Costello, Eithne , Zambon, Carlo‐Federico , Kupčinskas, Juozas , Bracci, Paige M. , Pezzilli, Raffaele , Olson, Sara H. , Sesso, Howard D. , Hartge, Patricia, Strobel, Oliver , Małecka‐Panas, Ewa , Visvanathan, Kala , Arslan, Alan A. , Pedrazzoli, Sergio , Souček, Pavel , Gioffreda, Domenica , Talar‐Wojnarowska, Renata , Scarpa, Aldo , Mambrini, Andrea , Jacobs, Eric J. , Jamroziak, Krzysztof , Tavano, Francesca , Bambi, Franco , Landi, Stefano , Austin, Melissa A. , Vodičková, Ludmila, Brenner, Hermann , Fave, Gianfranco Delle, Piepoli, Ada, Cantore, Maurizio , Zheng, Wei , Wolpin, Brian M. , Ámundadóttir, Laufey T. , Canzian, Federico , Wang, Zhaoming , Salvia, Roberto , Stolzenberg‐Solomon, Rachael Z. , Gazouli, Maria , Wang, Zhaoming , Kooperberg, Charles , Sperti, Cosimo , Wareham, Nicholas J. , Kupcinskas, Juozas , Risch, Harvey A. , Kraft, Peter , Key, Tim , Klein, Alison P. , Chanock, Stephen Jacob , Amundadottir, Laufey , Arslan, Alan A , Canzian, Federico , Wang, Zhaoming , Visvanathan, Kala , Brenner, Hermann , Strobel, Oliver , Zheng, Wei , Cleary, Sean P , Vodicka, Pavel , Landi, Stefano , Holcatova, Ivana , Tavano, Francesca

Mayo Clinic

International Journal of Cancer | May 5, 2015 | Volume: 137 | Issue: 9 | Pages: 2175-2183

10.1002/ijc.29590 | PMID 25940397 Get It

A small number of common susceptibility loci have been identified for pancreatic cancer, one of which is marked by rs401681 in the TERT–CLPTM1L gene region on chromosome 5p15.33. Because this region is characterized by low linkage disequilibrium, we sought to identify whether additional single nucleotide polymorphisms (SNPs) could be related to pancreatic cancer risk, independently of rs401681. We performed an in‐depth analysis of genetic variability of the telomerase reverse transcriptase (TERT) and the telomerase RNA component (TERC) genes, in 5,550 subjects with pancreatic cancer and 7,585 controls from the PANcreatic Disease ReseArch (PANDoRA) and the PanScan consortia. We identified a significant association between a variant in TERT and pancreatic cancer risk (rs2853677, odds ratio = 0.85; 95% confidence interval = 0.80–0.90, p = 8.3 × 10−8). Additional analysis adjusting rs2853677 for rs401681 indicated that the two SNPs are independently associated with pancreatic cancer risk, as suggested by the low linkage disequilibrium between them (r2 = 0.07, D′ = 0.28). Three additional SNPs in TERT reached statistical significance after correction for multiple testing: rs2736100 (p = 3.0 × 10−5), rs4583925 (p = 4.0 × 10−5) and rs2735948 (p = 5.0 × 10−5). In conclusion, we confirmed that the TERT locus is associated with pancreatic cancer risk, possibly through several independent variants.
Abstract OT2-3-01: SGN-LIV1A: A phase 1 trial evaluating a novel antibody-drug conjugate in patients with LIV-1-positive breast cancer
Forero, Andres , Burris, Howard A. , LoRusso, Patricia , Specht, Jennifer M. , Mita, Monica , Liu, Minetta C. , Sussman, Django, Kostić, Ana , Miller, Kathy D. , Modi, Shanu , Pusztai, Lajos , Specht, Jennifer

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 75 | Issue: 9_Supplement | Pages: OT2-3-01-OT2-3-01

10.1158/1538-7445.sabcs14-ot2-3-01 Get It

Abstract Background First identified as an estrogen-inducible gene in a breast cancer cell line, LIV-1 is a multispan transmembrane protein of the solute-carrier family 39 with putative zinc transporter and metalloproteinase activity. As a downstream target of STAT3, it promotes the epithelial-to-mesenchymal transition that is important in the malignant progression to metastasis. LIV-1 is expressed in a number of cancers with the highest prevalence and level of expression in breast, prostate, and melanoma. Additionally, LIV-1 has been linked with malignant progression to metastasis and associated with lymph node involvement in breast cancer. Normal tissue expression is predominantly limited to hormonally regulated tissues, including breast and prostate. In metastatic breast cancer tissue samples, the current validated immunohistochemistry assay for LIV-1 has detected moderate to high expression in 82% of samples tested, with 88% positivity in hormone receptor-positive tumors and 73% in triple-negative tumors. SGN-LIV1A is an antibody-drug conjugate (ADC) composed of a humanized anti-LIV-1 monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. In vitro, SGN-LIV1A shows target-specific internalization and cytotoxic activity against LIV-1-positive neoplastic cell lines. Significant dose-dependent tumor regression was demonstrated in mouse xenograft models. Methods The primary objective of this first-in-human phase 1, open label, multicenter study is to evaluate the safety and tolerability, and to identify the maximum tolerated dose of SGN-LIV1A using a 3+3 dose-escalation study design. Pharmacokinetics, immunogenicity, and antitumor activity will also be evaluated (ClinicalTrials.gov #NCT01969643). Enrollment to this US-based trial began in late 2013. Eligible patients are adult females who have hormone receptor-positive/HER2-negative or triple-negative metastatic breast cancer. Tumor tissue must be positive for expression of LIV-1 per central assessment. Patients must have received at least 2 prior cytotoxic regimens in the metastatic setting and have measurable disease per RECIST v1.1. Pre-existing neuropathy ≥ Grade 2 is not permitted. SGN-LIV1A is administered intravenously every 3 weeks at protocol-defined doses starting at 0.5 mg/kg. Patients who achieve an objective response or stable disease per RECIST v1.1 are eligible to continue treatment until disease progression. At the completion of dose escalation, expansion cohorts may be opened to enroll patients with specific breast cancer subtypes to further define safety and antitumor activity. Tumor biopsies are being obtained at baseline and after one cycle of treatment to evaluate the role of LIV-1 expression, target saturation, and other tumor-specific measurements in the antitumor activity of SGN-LIV1A. Citation Format: Andres Forero, Howard Burris III, Patricia LoRusso, Jennifer Specht, Kathy Miller, Monica Mita, Minetta C Liu, Shanu Modi, Lajos Pusztai, Django Sussman, Ana Kostic. SGN-LIV1A: A phase 1 trial evaluating a novel antibody-drug conjugate in patients with LIV-1-positive breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr OT2-3-01.
Abstract B58: EGFR and IR/IGFR activation sustains ERK1/2 and AKT signaling independently of mutant Kras in pancreatic cancer cells lines
Takeuchi, Kenneth K., Crawford, Howard C.

Mayo Clinic

Molecular Cancer Research | May 4, 2015 | Volume: 12 | Issue: 12_Supplement | Pages: B58-B58

10.1158/1557-3125.rasonc14-b58 Get It

Abstract Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related death in the United States. Roughly 45,000 patients are diagnosed with the disease each year and of these patients 94% will not survive past 5 years. The most common genetic alteration associated with PDAC is an oncogenic mutation in the KRAS gene, which is believed to initiate the disease. Mutant Kras is generally thought to signal constitutively to its downstream effector proteins, such as Raf/MEK/Erk and PI3K/AKT. However, recently we and others have demonstrated that Epidermal Growth Factor Receptor (EGFR) signaling upstream of mutant Kras is necessary for unlocking its oncogenic potential in the pancreas, distinct from Kras driven tumorigenesis in the lung or colon. Unfortunately, while EGFR inhibition is effective in blocking pancreatic tumorigenesis in mice, it has limited benefit in treating human PDAC patients. Furthermore, it has been shown that wild-type Nras and Hras have indispensable signaling roles in cells expressing oncogenic Kras, and that both the mutant and WT Ras signals are required for cell growth. Here we show that pancreatic cancer cell lines containing oncogenic Kras still require upstream signaling to maintain high levels of both active Erk and AKT although these signals are not necessarily EGFR derived. We have identified a subset of pancreatic cancer cell lines that rely upon IR/IGFR signaling to maintain the high levels of Erk and AKT signaling required for continued cell growth. Additionally, this signaling appears to be independent of oncogenic Kras and instead correlates with the levels of active wild-type Nras and Hras. This data indicates that patients may benefit from the simultaneous inhibition of both the EGFR and IR/IGFR signaling pathways. Citation Format: Kenneth K. Takeuchi, Howard C. Crawford. EGFR and IR/IGFR activation sustains ERK1/2 and AKT signaling independently of mutant Kras in pancreatic cancer cells lines. [abstract]. In: Proceedings of the AACR Special Conference on RAS Oncogenes: From Biology to Therapy; Feb 24-27, 2014; Lake Buena Vista, FL. Philadelphia (PA): AACR; Mol Cancer Res 2014;12(12 Suppl):Abstract nr B58. doi: 10.1158/1557-3125.RASONC14-B58
Abstract A23: Oncogenic Ras induces inflammatory cytokine production by upregulating squamous cell carcinoma antigen (SerpinB3)
Catanzaro, Joseph M., Sheshadri, Namratha , Pan, Ji-An, Shi, Chanjuan , Zong, Wei‐Xing , Pan, Ji-An, Sun, Yu , Li, Jinyu , Powers, Scott , Crawford, Howard C.

Mayo Clinic

Molecular Cancer Research | May 4, 2015 | Volume: 12 | Issue: 12_Supplement | Pages: A23-A23

10.1158/1557-3125.rasonc14-a23 Get It

Abstract Mounting evidence indicates that oncogenic Ras can modulate cell autonomous inflammatory cytokine production, although the underlying mechanism remains unclear. Here we show that squamous cell carcinoma antigen (SCCA), a member of the Serpin family of serine/cysteine protease inhibitors, is transcriptionally up-regulated by oncogenic Ras via MAPK and the ETS family transcription factor PEA3. Increased SCCA expression leads to inhibition of protein turnover, unfolded protein response (UPR), activation of NF-κB, and is essential for Ras-mediated cytokine production and tumor growth. Analysis of human colorectal and pancreatic tumor samples reveals a positive correlation between Ras mutation, enhanced SCCA expression, and IL-6 expression. These results indicate that SCCA is a Ras-responsive factor that plays an essential role in Ras-associated cytokine production and tumorigenesis. Citation Format: Joseph Catanzaro, Namratha Sheshadri, Ji-An Pan, Yu Sun, Chanjuan Shi, Jinyu Li, Scott Powers, Howard Crawford, Wei-Xing Zong. Oncogenic Ras induces inflammatory cytokine production by upregulating squamous cell carcinoma antigen (SerpinB3). [abstract]. In: Proceedings of the AACR Special Conference on RAS Oncogenes: From Biology to Therapy; Feb 24-27, 2014; Lake Buena Vista, FL. Philadelphia (PA): AACR; Mol Cancer Res 2014;12(12 Suppl):Abstract nr A23. doi: 10.1158/1557-3125.RASONC14-A23
Abstract A09: Notch signaling couples with Kras or PI3K to drive EGFR independent pancreatic acinar to ductal metaplasia
Halbrook, Christopher J. , Crawford, Howard C.

Mayo Clinic

Molecular Cancer Research | May 4, 2015 | Volume: 12 | Issue: 12_Supplement | Pages: A09-A09

10.1158/1557-3125.rasonc14-a09 Get It

Abstract Almost all reported cases of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, harbor an oncogenic Kras mutation. Recently, targeting oncogenic Kras to specific cell types in the adult pancreas has shown the acinar compartment to be more susceptible to neoplastic transformation than ductal cells. Acinar to ductal metaplasia (ADM) is a phenomenon where acinar cells undergo a morphological change and begin expressing markers normally found only in ductal cells while losing markers typical of acinar cells. ADM is highly proliferative with the potential to develop into pancreatic intraepithelial neoplasias, a precursor lesion to pancreatic cancer. Acinar cells harvested from mice expressing mutant Kras undergo spontaneous ADM when embedded in 3D collagen cultures, however, we and others have found the epidermal growth factor receptor (EGFR) is required for ADM induced by mutant Kras expression in vitro. Activation of EGFR by treatment of WT collagen embedded acinar cell explants with the EGFR ligand TGF-α has also been shown to induce ADM in a manner requiring Notch pathway activation. Furthermore, it has been demonstrated that expression of Notch2 intracellular domain (N2ICD) is sufficient to induce ADM in WT acinar cells. To directly investigate the relationship of the EGFR, Kras, and Notch signaling pathways in ADM, we examined the effect of Notch signaling in acinar cells harvested from EGFRf/f; Ptf1a+/Cre (EKO) mice, which harbor a pancreas specific deletion of EGFR. Surprisingly, we found that expression of N2ICD failed to induce ADM in acinar cells from EKO mice. We also observed that co-expression of a constitutively active p110α mutant or mutant Kras with N2ICD was able to rescue ADM in acinar cells from EKO mice, though neither was sufficient to drive ADM in the absence of N2ICD. Additionally, treatment of acinar cells from WT mice with either the p110α inhibitor Pik75 or the expression of a dominant negative mutant of the PI3K downstream target Rac1 reduced Erk1/2 phosphorylation, whereas expression of constitutively active p110α increased the level of Erk1/2 phosphorylation. These results demonstrate the importance of EGFR signaling in ADM, and identify the need to determine the mechanism of crosstalk between the PI3K and MAPK pathways in acinar cells. Citation Format: Christopher J. Halbrook, Howard C. Crawford. Notch signaling couples with Kras or PI3K to drive EGFR independent pancreatic acinar to ductal metaplasia. [abstract]. In: Proceedings of the AACR Special Conference on RAS Oncogenes: From Biology to Therapy; Feb 24-27, 2014; Lake Buena Vista, FL. Philadelphia (PA): AACR; Mol Cancer Res 2014;12(12 Suppl):Abstract nr A09. doi: 10.1158/1557-3125.RASONC14-A09
Abstract 4631: Pharmacokinetics and in vivo metabolism of Z-endoxifen: Results from two phase I studies in women with ER+ breast cancer, gynecologic malignancies and desmoids
Kumar, Shivaani, McGovern, Renee M., Buhrow, Sarah A. , Docktor, Travis J., Erlichman, Charles , Streicher, Howard , Doroshow, James H. , Collins, Jerry M. , Ames, Matthew M. , Reid, Joel M. , Goetz, Matthew P. , Safgren, Stephanie L. , Suman, Vera J.

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 4631-4631

10.1158/1538-7445.am2014-4631 Get It

Abstract Background: Breast cancer recurrence has been shown to differ based upon CYP2D6 genotype and endoxifen (Endx) exposure following treatment with tamoxifen (TAM) in the adjuvant setting. The average Endx Css is 29 nM (range, 2-80 nM) in TAM treated patients at a dose of 20 mg/day. Administration of Endx itself to patients is predicted to provide adequate, consistent, active drug levels in all treated patients, resulting in clinical benefit. As part of two phase 1 trials of oral Endx to determine the safety, tolerability, and MTD, we characterized the pharmacokinetics and in vivo metabolism of Endx. Methods: Patients were given escalating daily oral doses of Endx (28 day cycle) over the dose range of 20 - 160 mg/day in Phase I trials at the Mayo Clinic and NCI. Pharmacokinetics sampling was performed on days 1, 7, 14 and 28, and prior to subsequent cycles. Endx plasma concentrations and metabolite profiles were determined by HPLC and LC/MS/MS. Results: 44 patients with ECOG PS 0-1 have been enrolled to date encompassing 8 dose levels in the Mayo (25 women with AI refractory MBC; median age 58 yrs, range 41-83 yrs) and NCI (19 women with ovary (9), breast (4), desmoid (2), fallopian tube (2), endometrial cancer (2); median age 64 yrs, range 43-75 yrs) studies. Day 1 Endx peak concentrations (Cmax) were reached 4h after the Endx oral dose and mean values of Cmax, C24h, and AUC0-24h increased in proportion to dose. Css was achieved on day 7 and 3.5-fold accumulation (t1/2= 50.5 h) was observed on day 28. At the starting dose ( 20 mg/day) and highest dose level (160 mg/day), Endx Css values of 146 ng/ml (390 nM) and 1950 ng/ml (5200 nM), respectively, were achieved and maintained throughout the 28-day treatment. Endx Css values remained unchanged following continuous dosing for 8-10 months. The mean apparent steady-state clearance was 6.2 L/h. We also characterized the Endx metabolite profile in patient plasma and urine. Metabolites detected in plasma include nor-Endx, N-hydroxy-Endx, Endx-catechol, methoxy-Endx catechol, and Endx-glucuronide, and appear in amounts much lower compared to Endx. Like the parent drug, metabolites accumulated in plasma over the 28-day cycle. Characterization of the pharmacokinetics of Nor-Endx, a putative aromatase inhibitor, is ongoing and will be presented. Conclusion: In these ongoing Phase I studies, daily administration of Endx is well tolerated with Css consistently above those obtained following administration of standard dose tamoxifen. In the Mayo study, expansion at 20 and 100 mg/day has commenced to perform translational studies and further characterize Endx PK. In the NCI study, dose escalation continues to establish the maximum tolerated dose. Supported in part by R01CA 133049, U01 CA69912, P30CA 15083, P50CA 116201 and NCI Contracts CM52206 and HHSN261201100014C. Citation Format: Joel M. Reid, Matthew P. Goetz, Shivaani Kumar, Renee M. McGovern, Sarah A. Buhrow, Stephanie L. Safgren, Vera J. Suman, Travis J. Docktor, Charles Erlichman, Howard Streicher, James H. Doroshow, Jerry Collins, Matthew M. Ames. Pharmacokinetics and in vivo metabolism of Z-endoxifen: Results from two phase I studies in women with ER+ breast cancer, gynecologic malignancies and desmoids. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4631. doi:10.1158/1538-7445.AM2014-4631
Abstract 3285: Functional analysis of the 9p22 locus implicates the transcriptional regulation of BNC2 as a mechanism in ovarian cancer predisposition
Buckley, Melissa A., Shen, Howard C., Mendoza-Fandiño, Gustavo, Gjyshi, Anxhela, Lawrenson, Kate , Song, Honglin , Valle, Alexandra, Chen, Ann , Yoder, Sean J., Bloom, Gregory, Yang, Ally , Qu, Xiaotao , Cicek, Mine S., Larson, Melissa A., Goode, Ellen L. , Sellers, Thomas A. , Gayther, Simon A. , Woods, Nicholas T. , French, Juliet D. , Tyrer, Jonathan P. , Carvalho, Renato S. , Yoder, Sean , Hughes, Timothy R. , Fridley, Brooke L. , Ramus, Susan J. , Chenevix‐Trench, Georgia , Pharoah, Paul D.P. , Monteiro, Álvaro N.A. , Lawrenson, Kate

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 3285-3285

10.1158/1538-7445.am2014-3285 Get It

Abstract An ovarian cancer Genome Wide Association Study (GWAS) identified 9p22.2 as a novel susceptibility locus with the most statistically significant single nucleotide polymorphisms (SNPs) located in an intergenic region near the Basonuclin 2 (BNC2) gene, which codes for a putative transcription regulator containing three pairs of zinc finger (ZF) domains. The minor alleles are protective in terms of ovarian cancer susceptibility. However, the molecular mechanisms by which these SNPs modify susceptibility remain largely unknown. The significant SNPs in the 9p22.2 locus lie in non-coding regions and therefore are hypothesized to affect the activity of regulatory elements and modify the expression of a target gene(s). In order to test this hypothesis we conducted fine mapping for the locus which delimited a ∼74kb region containing SNPs with a p-value less than 10-8. FAIRE-Seq and ChIP-Seq experiments for histone markers conducted in immortalized ovarian surface epithelial cells (IOSE) and fallopian tube epithelial cells (IFTE) were used to prioritize functional SNP candidates which overlap with regulatory elements. Luciferase assays tested the ability of these regulatory elements to activate transcription. Chromosome conformation capture (3C) experiments demonstrate a physical interaction between the BNC2 promoter and candidate regulatory elements containing risk-associated SNPs. Methylation Quantification at Trait Loci (mQTL) revealed an association between decreased methylation at the BNC2 promoter and the protective minor alleles. Expression analysis shows decreased expression of BNC2 in cancer versus normal tissue implicating tumor suppressor function of BNC2. Therefore the protective minor allele likely increases expression of BNC2 which in turn contains tumor suppressing properties that decrease ovarian cancer risk. BNC2 protein is in complex with transcriptional regulatory proteins, in particular the NURD complex components. Moreover, BNC2 acts as a transcriptional repressor in in vitro transfection assays indicating that it functions in transcriptional repression. We then used protein binding microarrays and CHIP-Seq experiments to identify its putative DNA binding motifs and its downstream target genes. Analysis of this data suggests that BNC2 functions in a regulatory transcription network that impacts on genes implicated in ovarian cancer with enrichment for genes in the TGF-beta response pathway. Citation Format: Melissa A. Buckley, Howard C. Shen, Gustavo A. Mendoza-Fandino, Nicholas T. Woods, Anxhela Gjyshi, Juliet French, Kate Lawrenson, Honglin Song, Jonathan Tyrer, Renato S. Carvalho, Alexandra Valle, Ann Chen, Sean Yoder, Gregory Bloom, Ya-Yu Tsai, Ally Yang, Timothy R. Hughes, Xiaotao Qu, Mine Cicek, Melissa Larson, Ellen Goode, Brooke Fridley, Susan Ramus, Georgia Chenevix-Trench, Paul Pharoah, Thomas A. Sellers, Simon Gayther, Alvaro N.A. Monteiro, Ovarian Cancer Association Consortium. Functional analysis of the 9p22 locus implicates the transcriptional regulation of BNC2 as a mechanism in ovarian cancer predisposition. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3285. doi:10.1158/1538-7445.AM2014-3285
iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling
Li, Xue , Maretzky, Thorsten , Weskamp, Gisela, Monette, Sébastien , Qing, Xiaoping, Issuree, Priya D. , McIlwain, David R. , Mak, Tak W. , Blobel, Carl , Crawford, Howard C, Crawford, Howard C. , Salmon, Jane E.

Mayo Clinic

Proceedings of the National Academy of Sciences | April 30, 2015 | Volume: 112 | Issue: 19 | Pages: 6080-6085

10.1073/pnas.1505649112 | PMID 25918388 Get It

Significance The skin and intestinal barrier are controlled by signaling scissors, termed ADAM17 (a disintegrin and metalloprotease 17), that reside in the membrane on the surface of cells. The main purpose of these signaling scissors is to liberate growth factors from their membrane anchor, allowing them to activate their receptors, including the epidermal growth factor receptor (EGFR). The ADAM17/EGFR signaling axis is tightly regulated, yet little is known about the underlying mechanism. Here we use genetic, cell biological, and biochemical approaches to identify two membrane proteins termed iRhoms 1 and 2 (inactive Rhomboid-like proteins) as crucial upstream regulators of ADAM17-dependent EGFR signaling. This uncovers the iRhoms as attractive novel targets to treat ADAM17/EGFR-dependent diseases such as cancer.
Idiopathic Subglottic and Tracheal Stenosis
Gnagi, Sharon H. , Howard, Brittany E. , Anderson, Catherine , Lott, David G.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | April 24, 2015 | Volume: 124 | Issue: 9 | Pages: 734-739

10.1177/0003489415582255 | PMID 25910757 Get It

Objectives: To report and compare patients’ experiences with acquired subglottic stenosis (AS) versus idiopathic subglottic and tracheal stenosis (ISTS). Methods: A survey was made available to patients with AS and ISTS. Results were analyzed for inter- and intragroup differences using a 2-tailed t test. Results: The study included 160 survey participants (AS n = 28; ISTS n = 132), with a predominance of female participants (82% AS, 98% ISTS). Acid reflux was the most prevalent comorbidity across groups (42%-43%). A significant difference in time to diagnosis was found between groups, with 32% of AS patients diagnosed within 3 months of symptom onset, compared to 2% with ISTS. A diagnosis delay greater than 18 months occurred for 58% of ISTS patients. There was no difference in treatment approach, with the most common treatment being balloon dilation, followed by laser dilation. Tracheal resection was performed in 36% of patients in both groups. Patient satisfaction with surgical outcomes was significantly higher after tracheal resection (76%) compared to other treatment modalities (39%). Conclusions: ISTS remains a diagnostic challenge as highlighted by the delay in diagnosis compared to AS. There appears to be no historical or symptomatic factors specific to ISTS. Additionally, patients report increased satisfaction and symptom resolution after tracheal resection.
Impact of persistent minimal residual disease post‐consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report
Shiramizu, Bruce , Goldman, Stanton, Agsalda‐Garcia, Melissa, Galardy, Paul J. , Perkins, Sherrie L., Frazer, J. Kimble , Sanger, Warren G., Anderson, James R. , Gross, Thomas G. , Weinstein, Howard J., Harrison, Lauren , Barth, Matthew J. , Mussolin, Lara , Cairo, Mitchell S. , Galardy, Paul, Smith, Lynette M.

Mayo Clinic

British Journal of Haematology | April 9, 2015 | Volume: 170 | Issue: 3 | Pages: 367-371

10.1111/bjh.13443 | PMID 25858645 Get It

SummaryPatient‐specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French‐British‐American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real‐time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD‐positive at EOI and EOC, respectively, with no disease recurrences. MRD after induction and consolidation did not predict relapse and subsequent therapy appeared to eliminate MRD. Thus, assessing MRD at a later time point is warranted in future trials to determine its clinical significance.